BioCryst Pharmaceuticals
BCRX
73 hedge funds and large institutions have $217M invested in BioCryst Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 17 increasing their positions, 20 reducing their positions, and 15 closing their positions.
755% more capital invested
Capital invested by funds: $25.4M → $217M (+$192M)
67% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 15
64% more call options, than puts
Call options by funds: $4.96M | Put options by funds: $3.02M
16% more funds holding
Funds holding: 63 → 73 (+10)
15% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$29.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$13.3M |
| 3 |
DM
Deerfield Management
New York
|
+$8.28M |
| 4 |
VM
VHCP Management
New York
|
+$5.92M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$5.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$1.99M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.65M |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$1.13M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$917K |
| 5 |
Barclays
London,
United Kingdom
|
-$726K |
BCRX Hedge Fund Activity: Q3 2013 in Review
73 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q3 2013, worth a combined $217M — up 755% from $25.4M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new BCRX positions and 15 closed out — a net gain of 10 holders — while 17 added to existing stakes and 20 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $29.6M. The largest seller was Northern Trust, cutting an estimated $1.99M.
- 73 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q3 2013, up from 63 in Q2 2013.
- Funds reported $217M of BioCryst Pharmaceuticals stock for Q3 2013, up 755% quarter-over-quarter.
- 25 funds opened new BioCryst Pharmaceuticals positions in Q3 2013 and 15 closed out, a net change of +10 holders.
- The largest BioCryst Pharmaceuticals buyer in Q3 2013 was RA Capital Management, an estimated $29.6M added.
- The largest BioCryst Pharmaceuticals seller in Q3 2013 was Northern Trust, an estimated $1.99M sold.
Based on aggregated 13F filings for Q3 2013.